
    
      A total of up to 30 patients diagnosed of myelodysplastic syndrome red cell transfusion
      dependent with low or intermediate -1 risk will be included.

      The patients will be evaluated at scheduled visits in up to three study periods:
      Pre-treatment, Treatment and Follow up.

      The Pre-treatment includes Screening and baseline visits. After providing informed consent,
      patients will be evaluated for study eligibility.

      During Treatment Period patients will be evaluated once a month although biochemistry and
      haematology parameters will be evaluated every 2 weeks.

      If an erythroid response after 24 weeks is determined, a extension treatment will be carry
      out without disease progression.
    
  